Pharmacogenomics in clinical pediatrics
Progress in two major areas over the past 10 years has contributed to the understanding of pediatric disease and its pharmacologic management, writes . The first is a series of legislative changes targeted to improve drug therapy in children. In 1994, the Food and Drug Administration Pediatric Rule provided an avenue for manufacturers to insert information on the pharmacology and use of drugs in pediatric patients into approved product labeling. The second is the Human Genome Project, initiated in 1990 with the goal of sequencing the entire complement of human genes by the year 2005 which is expected to impact the diagnosis and treatment of pediatric diseases.
Pharmacogenomics and the challenge to privacy
The sheer magnitude of information resulting from pharmacogenomic analyses may yield a qualitative, disruptive change when compared to previous attempts to match drugs to genotypic variations. Yet even before its optimistic expectations materialize, suggest that pharmacogenomics is poised to challenge our current understanding of privacy. These studies will create large databases of genomic profiles. Stored DNA samples or digitized sequence information will contain the individual's probabilistic 'future diary', and as such are more vulnerable to violations of privacy.
Pharmacogenomics in oral health
The recent progress of the human and microbial genomes provides opportunities to understand the molecular basis of oral diseases, and design new generations of diagnostics, therapeutics 
5-HTTLPR and OCD treatment response
Recently, a role for a functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR) in conferring susceptibility to Obsessive Compulsive Disorder (OCD) has been suggested. The aim of the study by Di Bella et al (pages 176-181) was to test the hypothesis that allelic variation of the 5-HTTLPR could be associated with OCD susceptibility or influence the drug response in OCD.
Linkage disequilibrium flanking CYP2D6
Genotyping 1018 Caucasians for CYP2D6 polymorphisms known to result in the recessive CYP2D6 poor drug metaboliser (PM) phenotype, identified 41 individuals with predicted PM phenotype. The studies by LK Hosking et al (pages 165-175) supports the strategy for potential application of LD mapping and whole genome association scans to pharmacogenetic studies.
ABCB1 polymorphism and postural hypotension
The multi-drug resistance gene ABCB1 encodes a P-glycoprotein (P-gp) that regulates passage of many substances across the blood-brain barrier. The antidepressant amitriptyline and its metabolites are substrates for P-gp, and in mice lacking P-gp, penetration of amitriptyline, but not fluoxetine, into the brain is enhanced. The paper by RL Roberts et al (pages 191-196) reasons that polymorphic variation of P-gp may contribute to differing responses of patients to antidepressant drugs.
Acute coronary syndromes pharmacogenomics
Genetic variants are risk factors for coronary disease, but their role in recurrent events and in response to treatment is less clear. D Shields et al (pages 182-190) genotyped genetic variants implicated in primary coronary disease in 924 Caucasians with acute coronary syndromes participating in the OPUS-TIMI16 trial of the GPIIb/IIIa antagonist orbofiban. The results suggest a significant interaction of the polymorphisms with orbofiban treatment influencing bleeding outcomes. Thus, genetic polymorphisms may be associated with subsequent myocardial infarction, and may also be associated with treatment-associated bleeding among coronary patients.
Multi-locus interactions predict risk for post-PTCA restenosis
In the search for putative genetic factors predisposing to coronary artery restenosis following balloon angioplasty, RYL Zee et al (pages 197-201) determined genotypes for 94 SNPs representing 62 candidate genes. The results emphasize the need to account for complex multigene influences and interactions when assessing the molecular pathology of multifactorial medical entities.
